» Articles » PMID: 25372770

How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework Towards an Effective Response to HIV

Overview
Journal PLoS One
Date 2014 Nov 6
PMID 25372770
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In 2011 an Investment Framework was proposed that described how the scale-up of key HIV interventions could dramatically reduce new HIV infections and deaths in low and middle income countries by 2015. This framework included ambitious coverage goals for prevention and treatment services resulting in a reduction of new HIV infections by more than half. However, it also estimated a leveling in the number of new infections at about 1 million annually after 2015.

Methods: We modeled how the response to AIDS can be further expanded by scaling up antiretroviral treatment (ART) within the framework provided by the 2013 WHO treatment guidelines. We further explored the potential contributions of new prevention technologies: 'Test and Treat', pre-exposure prophylaxis and an HIV vaccine.

Findings: Immediate aggressive scale up of existing approaches including the 2013 WHO guidelines could reduce new infections by 80%. A 'Test and Treat' approach could further reduce new infections. This could be further enhanced by a future highly effective pre-exposure prophylaxis and an HIV vaccine, so that a combination of all four approaches could reduce new infections to as low as 80,000 per year by 2050 and annual AIDS deaths to 260,000.

Interpretation: In a set of ambitious scenarios, we find that immediate implementation of the 2013 WHO antiretroviral therapy guidelines could reduce new HIV infections by 80%. Further reductions may be achieved by moving to a 'Test and Treat' approach, and eventually by adding a highly effective pre-exposure prophylaxis and an HIV vaccine, if they become available.

Citing Articles

Comparison of Empirically Derived and Model-Based Estimates of Key Population HIV Incidence and the Distribution of New Infections by Population Group in Sub-Saharan Africa.

Stevens O, Anderson R, Stover J, Teng Y, Stannah J, Silhol R J Acquir Immune Defic Syndr. 2024; 95(1S):e46-e58.

PMID: 38180738 PMC: 10769165. DOI: 10.1097/QAI.0000000000003321.


A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study.

Moolla H, Phillips A, Ten Brink D, Mudimu E, Stover J, Bansi-Matharu L BMC Public Health. 2023; 23(1):2119.

PMID: 37891514 PMC: 10612295. DOI: 10.1186/s12889-023-16995-9.


Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.

Castor D, Heck C, Quigee D, Telrandhe N, Kui K, Wu J J Int AIDS Soc. 2023; 26 Suppl 2:e26110.

PMID: 37439063 PMC: 10339010. DOI: 10.1002/jia2.26110.


Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.

Mattathil J, Volz A, Onabajo O, Maynard S, Bixler S, Shen X Nat Commun. 2023; 14(1):1264.

PMID: 36882405 PMC: 9990026. DOI: 10.1038/s41467-023-36907-0.


The impact of condom use on the HIV epidemic.

Stover J, Teng Y Gates Open Res. 2022; 5:91.

PMID: 35355689 PMC: 8933340. DOI: 10.12688/gatesopenres.13278.2.


References
1.
Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

2.
Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D . Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013; 27(7):1159-65. PMC: 4539010. DOI: 10.1097/QAD.0b013e32835f1d68. View

3.
Montaner J . Treatment as prevention--a double hat-trick. Lancet. 2011; 378(9787):208-9. DOI: 10.1016/S0140-6736(11)60821-0. View

4.
Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

5.
Eaton J, Menzies N, Stover J, Cambiano V, Chindelevitch L, Cori A . Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014; 2(1):e23-34. DOI: 10.1016/S2214-109X(13)70172-4. View